EUCTR2020-004125-23-BE进行中（未招募）1 期
Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma - ADDICT-pedGLIO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnosis of HGG (WHO grade III or IV, histologically verified) or DIPG (verified by radiologic criteria (magnetic resonance imaging (MRI)) or by histology. A biopsy is not required but recommended.)
- •- Aged = 12 months and < 18 years at the time of signing the informed consent
- •- Body weight = 10 kg
- •- Lansky score (for patients < 16 years) or Karnofsky score (for patients = 16 years) of = 50
- •- Reasonable life expectancy = 8 weeks, as estimated by the treating physician
- •- Adequate hematological blood values and sufficient recovery from treatment-related toxicities (> grade 1) following previous anti-glioma treatments, as judged by the treating physician (applies to stratum B only).
- •- Written informed consent of parents or legal guardian and of patients aged 12 years or older. Written informed consent of patients younger than 12 years is optional.
- •- Willing and able to comply with the protocol, as judged by the treating physician
- •- Female patients of child bearing potential must have a negative serum or urine pregnancy test at the time of screening. Female patients of child bearing potential and male patients must agree to use effective contraception before, during and for at least hundred days after the last study treatment administration. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until at least hundred days after the last study treatment administration.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Use of any investigational agents = 4 weeks before the planned day of leukapheresis.
- •- Concomitant malignancy or history of another malignancy (unless the Investigator rationalizes otherwise)
- •- Known concomitant presence of any active immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo
- •- Any pre-existing contra-indication for contrast-enhanced MRI
- •- Pregnant or breastfeeding
- •- Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of the vaccine, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications
研究者
相似试验
已完成
2 期
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesotheliomaasbestos cancerperitoneal mesenthelioma10027412NL-OMON48572Erasmus MC, Universitair Medisch Centrum Rotterdam18
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
进行中（未招募）
不适用
Forsøg med dendritcellevaccination i kombination med kemoterapi til behandling af patienter med prostatakræft, der har spredt sigCastration resistent metastatic prostate cancerMedDRA version: 14.1Level: HLTClassification code 10036908Term: Prostatic neoplasms malignantSystem Organ Class: 100000004864EUCTR2011-001602-10-DKCenter for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital
进行中（未招募）
1 期
Complementary vaccination with dendritic cells pulsed with autologous tumor lysate in resected stage III and IV melanoma patients: a phase II randomized trial (ACDC adjuvant Trial)resected stage III and IV melanomaMedDRA version: 20.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005123-27-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS120